Non-Statin Therapies: Cost Effectiveness and Clinical Evidence Gaps

The expert panel discusses the cost-effectiveness and clinical evidence gaps for non-statin therapies, including PCSK9 inhibitors, inclisiran, and bempedoic acid.

EP: 1.How Often Do Patients with ASCVD Achieve Target LDL-C?

EP: 2.Gaps Between Guidelines and Clinical Practice Patterns in ASCVD

EP: 3.Comparing the ACC/AHA and ESC/EAS Cholesterol Management Guidelines

EP: 4.Key Barriers in Implementing Guideline-Directed Cholesterol Treatment

EP: 5.Evaluating Non-Statin Lipid-Lowering Therapies in ASCVD

EP: 6.Clinical Efficacy of Non-Statin Treatment Options in ASCVD

Now Viewing

EP: 7.Non-Statin Therapies: Cost Effectiveness and Clinical Evidence Gaps

EP: 8.Persistence and Discontinuation Rates for Non-Statin Therapies in ASCVD

EP: 9.The Role of Pharmacists in Treating Very High-Risk ASCVD

EP: 10.Valuable Metrics and Improving Adherence in Patients With ASCVD

EP: 11.Successful Collaborative Care Strategies for Pharmacists

Related Videos

Related Content

Advertisement

March 30th 2025

ACC 2025: Intravenous Iron Safe, but Results in Mixed Findings for Patients With Heart Failure

Aislinn Antrim, Managing Editor

April 1st 2025

Everything You Need to Know From the American College of Cardiology 2025 Scientific Session

Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPS-AQ Cardiology, CACP Aislinn Antrim, Managing Editor

March 29th 2025

ACC 2025: Dapagliflozin Found Safe, Effective in Older Adults With Heart Failure Undergoing Valve Replacement

Aislinn Antrim, Managing Editor

March 25th 2025

Introducing the Tell-Tale Heart Podcast

Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPS-AQ Cardiology, CACP

March 29th 2025

ACC 2025: Lower-Dose Apixaban Is Effective, Safer Than Full Dose for Preventing VTE Recurrence in Patients With Cancer

Aislinn Antrim, Managing Editor

March 29th 2025

ACC 2025: Semaglutide Significantly Improves Walking Distance, Symptoms, QOL for Individuals with PAD and Diabetes

Aislinn Antrim, Managing Editor

Related Content

Advertisement

March 30th 2025

ACC 2025: Intravenous Iron Safe, but Results in Mixed Findings for Patients With Heart Failure

Aislinn Antrim, Managing Editor

April 1st 2025

Everything You Need to Know From the American College of Cardiology 2025 Scientific Session

Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPS-AQ Cardiology, CACP Aislinn Antrim, Managing Editor

March 29th 2025

ACC 2025: Dapagliflozin Found Safe, Effective in Older Adults With Heart Failure Undergoing Valve Replacement

Aislinn Antrim, Managing Editor

March 25th 2025

Introducing the Tell-Tale Heart Podcast

Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPS-AQ Cardiology, CACP

March 29th 2025

ACC 2025: Lower-Dose Apixaban Is Effective, Safer Than Full Dose for Preventing VTE Recurrence in Patients With Cancer

Aislinn Antrim, Managing Editor

March 29th 2025

ACC 2025: Semaglutide Significantly Improves Walking Distance, Symptoms, QOL for Individuals with PAD and Diabetes

Aislinn Antrim, Managing Editor